SecBot SecBot

TVTX drug pipeline

$49.70
−1.9% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±15.2%
1-day, median of 6 events
IV rank
No data
No current options data
Rated drugs
2
2 neutral
Phase 3 trials
2
2 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 3
Time to marketIf the Phase 3 HARMONY study succeeds, a regulatory filing could follow the topline data (expected 2H 2027), with potential FDA approval potentially 12-18 months later, suggesting a possible 2029-2030 launch at the earliest.

pegtibatinase Updated Nov 2

What to watch

The next major catalyst is the Phase 3 HARMONY topline data readout in 2H 2027. Positive data would position pegtibatinase as the first disease-modifying therapy for classical HCU and likely drive significant upside. Negative data or further manufacturing delays would be substantially damaging, though FILSPARI revenues provide a partial buffer.

Bull case
  • Phase 1/2 COMPOSE data showed a 67.1% mean relative reduction in total homocysteine at the highest dose, a strong efficacy signal for a therapy with no currently approved disease-modifying alternative.
  • Pegtibatinase has been granted FDA Breakthrough Therapy, Rare Pediatric Disease, Fast Track, and US/EU Orphan Drug designations, which could accelerate regulatory review and provide market exclusivity.
  • Multiple sophisticated institutional investors (including Adage Capital, Bank of America, Point72, Marshall Wace, D.E. Shaw, and Wellington Management) added or doubled positions in Q2 2026.
Bear case
  • Manufacturing scale-up problems forced a voluntary enrollment pause of the Phase 3 HARMONY study from September 2024 until Q1 2026, raising execution risk and delaying the program by over a year.
  • The pivotal Phase 3 topline readout is not expected until the second half of 2027, leaving the stock without a near-term binary catalyst for this program for at least 8-14 months.
  • Classical HCU is an ultra-rare disease (estimated <3,000 patients in the US), limiting the commercial ceiling even if approved.
● neutral
Impact
PhasePhase 1b/2a (pMN study by Everest Medicines); pre-IND for Travere's planned trials
Time to marketYears away. Travere plans to file a U.S. IND by year-end 2026 and initiate late-stage studies, meaning pivotal readouts and any potential approval would be several years out, likely in the 2029-2031 timeframe if successful.

civorebrutinib Updated Nov 2

What to watch

Travere plans to submit a U.S. IND for civorebrutinib by year-end 2026, which would enable dosing studies. Look for IND acceptance and initial Phase 2 trial initiation in 2027. Pivotal readouts are likely years away. The stock's near-term catalysts remain FILSPARI sales execution and the Phase 3 HARMONY pegtibatinase topline data (expected 2H 2027).

Bull case
  • Proof-of-concept Phase 1b/2a data in pMN showed rapid and sustained reductions in anti-PLA2R autoantibodies (up to 93%) and proteinuria (78% through 52 weeks), a strong efficacy signal for a difficult-to-treat kidney disease.
  • As an oral, covalent reversible BTK inhibitor, civorebrutinib may offer a better safety profile than first-generation irreversible BTK inhibitors (e.g., ibrutinib), which have off-target toxicity concerns.
  • The drug has 'pipeline-in-a-product' potential across multiple immune-mediated kidney diseases (pMN, FSGS, MCD) with shared underlying mechanisms, expanding the addressable market.
Bear case
  • Civorebrutinib is still at the pre-pivotal stage; only Phase 1b/2a data exists, and those were generated by the partner (Everest) in a Chinese patient population, which may not generalize to global populations.
  • The BTK inhibitor class is highly competitive with 385+ drugs in development globally, primarily for oncology; standing out in kidney disease requires dedicated, expensive Phase 2/3 trials that may fail.
  • Travere paid $112.5 million upfront with up to $1.03 billion in milestones, a significant financial commitment for an unapproved asset, and the company reported a $52.3 million net loss in Q3 2026.

Other drugs in filings and trials

no drug report yet
  • FILSPARI Last: Approval · Apr 13, 2026
  • sparsentan Last: NDA filed · Jan 1, 2026

Past FDA events & how the stock moved

6 events
DateDrugEvent1 day5 days
Apr 13, 2026FILSPARIApproval+45.5%+39.1%
Apr 13, 2026FILSPARIPDUFA decision+45.5%+39.1%
Jan 13, 2026FILSPARIAdCom meeting−15.2%−17.2%
Jan 13, 2026FILSPARIPDUFA decision−15.2%−17.2%
Jan 1, 2026sparsentanNDA filed+3.4%−6.8%
Feb 17, 2023FILSPARIApproval+4.9%+7.1%

Clinical trials

3 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
pegtibatinasePegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE)Phase 2Active not recruiting32Jun 2026
sparsentanA Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyPhase 3Completed · results406Aug 7, 2023
sparsentanStudy of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)Phase 3Completed · results371Mar 20, 2023